[Skip to Content]

Upstate Active Clinical Trials

Study Title:

Alliance A081105 - Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

What is the purpose of the study?

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Upstate Institutional Review Board (IRB) Number:

656609

Study/Protocol ID:

A081105

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

Where will the study take place?

Upstate Cancer Center-All procedures
Oneida-All procedures
Oswego-All procedures

ClinicalTrials.Gov ID:

NCT02193282

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Erinn Mcdowell, MS, CCRP
Phone: 315-464-8230
Email: mcdowele@upstate.edu

Return to Previous Page || Search Again

Top